• A Popular Alzheimer’s Biomarker Found at High Levels in Newborns

    Jul 16 | Bio-IT World | In recent years, phosphorylated tau has garnered so much attention as one of the “bad guys” of Alzheimer’s disease that the scientific community may have developed a bit of tunnel vision. A medical doctor in Sweden seeks to remedy the situation as a “champion” of the biomarker based on the critical if forgotten physiological role it plays in the healthy human brain. More

  • Pharma Companies Finding Their Way with AI

    Jul 15 | Bio-IT World | Massive progress has been enabled by individual applications of artificial intelligence (AI) and machine learning (ML) in drug discovery, AlphaFold being one of the most prominent, due to their ability to predict the type of molecules that should have a positive impact on patient care. More

  • Trends from the Trenches: What a TV Scientist Knows About Teaching Science

    Jul 10 | Bio-IT World | David Hewlett, renowned for portraying Dr. Rodney McKay in the Stargate franchise, recently joined Trends from the Trenches podcast to discuss the fascinating intersection of Hollywood, science communication, and lifelong learning. Hewlett and host Ari Berman explore how entertainment can serve as a powerful gateway to scientific curiosity and innovation. More

  • From Physics to Longevity: How Gero’s ProtoBind-Diff Tool Reads Nature’s Hidden Drug Library

    Jul 09 | Bio-IT World | Consumer genomics pioneer 23andMe will be returning to its co-founder and former CEO as Anne Wojcicki’s TTAM Research Institute outbids Regeneron to buy 23andMe out of bankruptcy—as long as no more state attorneys general object. The current iteration of the sale is expected to close on July 8. More

  • Population Genomics Projects Around the World Gaining Ground

    Jul 08 | Bio-IT World | Pangaea Data has entered into a collaboration agreement with Alexion to develop an Artificial Intelligence Clinical Decision Support System; Dell Technologies will develop NERSC-10, the next flagship supercomputer at the National Energy Research Scientific Computing Center; and more. More

  • Virtual Cell Challenge Announces Prize for AI Models of Cellular Response

    Jul 03 | Bio-IT World | In a commentary published last week in Cell, researchers from the Arc Institute introduced the “Virtual Cell Challenge,” a public competition with a grand prize worth $100,000 for the machine learning model that best predicts how cells will respond to genetic perturbations. More

  • Anne Wojcicki Buys Back 23andMe for $305M, Promises Data Security

    Jul 02 | Bio-IT World | Consumer genomics pioneer 23andMe will be returning to its co-founder and former CEO as Anne Wojcicki’s TTAM Research Institute outbids Regeneron to buy 23andMe out of bankruptcy—as long as no more state attorneys general object. The current iteration of the sale is expected to close on July 8. More

  • Real-Time Drug Monitoring: A New Era for Drug Discovery and Development

    Jul 01 | Bio-IT World | In Stanford University's engineering labs, Tom Soh has been wrestling with a paradox that has plagued medicine for decades. While modern jet engines generate terabytes of data every hour to prevent catastrophic failures, the human body gets monitored only during annual checkups or after something has already gone wrong. More

  • UK Study Demonstrates Real-World Value of Genetic Testing for Drug Prescribing

    Jun 26 | Bio-IT World | The UK's National Health Service is pioneering a new approach to precision medicine through pharmacogenomic testing that could transform how doctors prescribe medications and significantly reduce healthcare costs. Early results from the NHS PROGRESS trial suggest that genetic testing can guide prescribing decisions for nearly all patients, with one in four participants having their prescriptions adjusted for safer or more effective treatment. More

  • Follow the Money: ITM’s Gastroenteropancreatic Therapy, GRIN, Angelini Pharma Collaborates, More

    Jun 25 | Bio-IT World | ITM plans to use their financing to prepare for commercial readiness and potential market launch of the company’s lead candidate, n.c.a. 177Lu-edotreotide, which treats gastroenteropancreatic neuroendocrine tumors; GRIN and Angelini Pharma will develop and expand commercial rights outside of North America for GRIN's investigational drug radiprodil, which treats rare genetic epilepsies and neurodevelopmental disorders; and more. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!